Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

CIBC World Cuts CV Therapeutics to 'Sector Perform'


CIBC World downgraded CV Therapeutics (CVTX) to sector perform.

Analyst Matthew Geller says he's downgrading from sector outperform due to the delay in FDA approval for Ranexa, the company's angina treatment. He notes the FDA said, in a letter to the company, that it was positive on the efficacy of the drug, but indicated additional clinical information is needed.

Geller says he spoke with CV Therapeutics, which said the FDA would like to see additional trial(s) demonstrating safety and a positive risk/benefit ratio. He believes should additional trials be needed, and are successful, Ranexa's approval would most likely be delayed by about 18 months. Geller widened the $3.30 2004 loss estimate to a $3.83 loss.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus